May 14, 2020 / 06:20PM GMT
Geoffrey Christopher Meacham - BofA Merrill Lynch, Research Division - Research Analyst
Okay. Welcome, everyone. I'm Geoff Meacham. I'm the senior biopharma analyst here at BofA. And welcome to our Virtual Vegas Conference -- Healthcare Conference. We are thrilled this afternoon to have BioMarin. And speaking on behalf of BioMarin we have J.J. Bienaimé, who is Chairman and CEO; and Hank Fuchs, who is President, Worldwide Research & Development. Guys, are you on?
Henry J. Fuchs - BioMarin Pharmaceutical Inc. - President of Worldwide Research & Development
Yes.
Jean-Jacques Bienaimé,BioMarin Pharmaceutical Inc.-Chairman&CEO
We are.
Geoffrey Christopher Meacham - BofA Merrill Lynch, Research Division - Research Analyst
Okay. Great. So the format for today is that we'll have some questions with the team here. And of course, there are -- there's technology on the Veracast system to log in and e-mail a
Biomarin Pharmaceutical Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
